Hepion Pharmaceuticals (NASDAQ:HEPA) is up 5% after hours ahead of a presentation of data from four nonclinical studies demonstrating that CRV431 improved liver fibrosis in animal and human tissue models.
Chief Scientific Officer Dr. Daren Ure will be announce the results at the NASH-TAG 2020 Conference in Park City, UT this week.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.